Weekly injections of the GLP-1 semaglutide reduce alcohol consumption in patients with obesity seeking treatment for alcohol use disorder.

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide ...

GLP-1 drugs tirzepatide and semaglutide may offer increased protection against heart attack, stroke and death from any cause, according to a November study published in Nature Medicine and presented ...

A new analysis of the STEP trials carried out by semaglutide manufacturer Novo Nordisk has analyzed various trials to show ...

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show ...

The study found that the active ingredient in GLP-1 drugs "significantly improved" motivation in patients with major ...

In a phase III trial, orforglipron yielded better HbA1c reduction compared with oral semaglutide at 52 weeks. Gastrointestinal side effects were more common with orforglipron, leading to more ...

A landmark clinical trial has found that semaglutide, a GLP-1 receptor agonist widely used for obesity, significantly reduced heavy drinking days in adults with alcohol use disorder (AUD) and obesity ...

Doctronic reports new AI analysis reveals GLP-1 medications may cause underreported symptoms like menstrual irregularities and fatigue.

Semaglutide, marketed as Ozempic and Wegovy, helps those over 65 years old lose weight and improve heart and metabolic health ...